Markets:

Overview

News

Currencies

International

Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

40.88 +0.11 (+0.28%)

Streaming Delayed Price Updated: 3:15 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Analyst Expectations for Castle Biosciences's Future ↗

May 04, 2023

Via Benzinga

Castle Biosciences Reports First Quarter 2023 Results

May 03, 2023

From Castle Biosciences, Inc.

Via Business Wire

Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

May 03, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

April 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

Looking Into Castle Biosciences's Return On Capital Employed ↗

November 16, 2022

Via Benzinga

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients

April 25, 2023

From Castle Biosciences, Inc.

Via Business Wire

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

April 20, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

April 19, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

From Castle Biosciences, Inc.

Via Business Wire

7 Value Stocks to Buy for Long-Term Growth ↗

March 26, 2023

If you have the patience to ride out some choppy weather, these value stocks to buy may offer significant upside later.

Via InvestorPlace

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

March 18, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

March 14, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2023

From Castle Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 08, 2023

Via Benzinga

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

March 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results

February 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

February 24, 2023

From Castle Biosciences, Inc.

Via Business Wire

Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

February 22, 2023

From Castle Biosciences, Inc.

Via Business Wire

Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines

February 09, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

February 07, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

February 01, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023

January 23, 2023

From Castle Biosciences, Inc.

Via Business Wire

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

January 17, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

January 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

November 21, 2022

From Castle Biosciences, Inc.

Via Business Wire

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

November 17, 2022

From Castle Biosciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

November 15, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

November 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts ↗

November 07, 2022

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.